The pharmaceutical unit dose packaging market is expected to experience a change in its operations, as manufacturers are focusing towards increasing productivity through integration of automation systems, as per a study by Future Market Insights (FMI). According to the report, the market will surpass US$ 26.10 Bn by 2021, registering a double-digit year-on-year (Y-o-Y) growth between 2020 and 2021.
The dynamic shift from manual to automatic packing lines is in turn expected to increase process efficiency and reduce dependence on the workforce, making it a cost-effective proposition in the long run. Rising demand for prefilled syringes for vaccination programs is expected to be a key trend, which would positively affect the pharmaceutical unit dose packaging market.
To Get Sample Copy of Report Visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5236
Automated packaging lines are also multitasking, which covers numerous steps of the packaging process such as forming, filling, sealing and labeling into single step. The designers of packaging line automation systems are prioritizing the design of human-machine interfaces (HMIs) to streamline processes. These enhanced HMI can sort it simpler for operators and managers to access information related to specific packaging production line.
The above trend is expected to be backed by increasing availability of biotechnology products with specific requirements for packaging such as prefilled syringes and single-use vials. Vials and prefilled syringes are two of the most common forms of pharmaceutical unit dose packaging, typically preferred in clinical research and diagnostic centers.
Vials and blisters have been identified as the most prominently used products in the pharmaceutical unit dose packaging market. Manufactures are vigorously ramping up for their facilities of vials production in anticipation of the demand for COVID-19 vaccine supply from all over the world. Thus, the segment is projected to expand 5.7x its current value during the forecast period.
Key Takeaways from Pharmaceutical Unit Dose Packaging Market ADVERTISEMENT
Pharmaceutical unit dose packaging sales will surge at 14.7% CAGR between 2021 and 2031
The presence of several leading players has enabled the U.S. account for over 87% of sales in North America in 2021
Rising research and development initiatives enabling the U.K. exhibit over 15% y-o-y growth in 2021
Surging healthcare spending has been fuelling the demand in Germany and France
Increasing demand for vaccination amid COVID-19 fuelling sales in China, Japan, and South Korea
“Some of the leading players are aiming at intensifying their production facilities to cater to the rising demand for vials and prefilled syringes to aid COVID-19 vaccination drives,” says FMI analyst.
For More Details, Ask Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-5236
Pharmaceutical Unit Dose Packaging Market Players Focusing on Geographic Expansion
As per FMI analysis, some of the leading manufacturing companies within pharmaceutical industry have been aiming at expanding their footprint, especially in remote areas with unmet medical needs. The demand for smaller packaging solutions such as blisters is considerably high in these regions. Furthermore, pharmaceutical unit dose supplying strategy includes getting some medicines in bulk quantities and repackaging them into single or unit dose, using high volume repackaging systems and some manual repackaging machines.
Cost saving is a key benefit of locally repackaging of medicines into unit dose, using high volume automated repackaging systems. Unit Dose Solutions, Inc., Safecor Health, Almac Group are some of the players who are active in repackaging services.
Impact of COVID-19 on Pharmaceutical Unit Dose Packaging Market
Global pharmaceutical unit dose packaging market is anticipated to exhibit impressive growth amid the emerging second wave of the COVID-19 pandemic. This is mainly due to the robust demand of drugs, medicines and vaccines from diagnostic centres, hospitals, and other healthcare units, who constitute the leading consumers of pharmaceutical unit dose packaging.
Blisters and vials will continue to attract massive investments from investors in orals and injectable pharmaceutical unit dose packaging end uses. According to FMI analysis, global adoption of pharmaceutical unit dose packaging will surge nearly 3.0x over 2021-2031.
QR codes and RFID tags have already been in use by pharmaceutical unit dose packaging manufacturers to ensure safer transportation of vaccines. The market is witnessing sharp growth in the usage of automation and robotics. For instance, a novel technology is adopted by Pfizer, Inc. for packing the vaccine doses due to be delivered in the USA. It is called “Ecoplat Plus” by ROBOPAC USA. It uses stretch film, a wrapping turntable incorporating state-of-the-art technology that guarantees advanced efficiency due to its durability, power and ease of use, including optimum safety of the products.
Pharmaceutical Unit Dose Packaging Market Landscape
UDG Healthcare plc, West Pharmaceutical Services, Inc., Schott AG, SGD SA, Stevanato Group S.p.a., Klockner Pentaplast Group, Amcor plc, Gerresheimer AG, Berry Global, Inc., Comar LLC, Constantia Flexibles Group GmbH, Nipro Corporation, Catalent, Inc., Becton, Dickinson and Company, Adelphi Healthcare Packaging, Winpak Ltd., Pacific Vial Manufacturing Inc., Sonoco Products Company, WestRock Company, and AptarGroup, Inc. are the prominent players in the pharmaceutical unit dose packaging market. The Tier 3 players in the market hold 75-85% in the global pharmaceutical unit dose packaging market. In conclusion, key players contribute almost 15-25% of the global demand.
Pharmaceutical Unit Dose Packaging Market Report
Future Market Insights, in its new report, offers an unbiased analysis of the global pharmaceutical unit dose packaging market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the pharmaceutical unit dose packaging market on the basis of product (blisters, ampoules, vials and prefilled syringes cartridges), material (plastic ((polyethylene (PE) (high density polyethylene (HDPE) and low density polyethylene (LDPE)), polypropylene, poly vinyl chloride (PVC), and polyethylene terephthalate (PET))), aluminum, glass and paper & paperboard) and end-use (ophthalmic, injectable, biologics, wound care, respiratory therapy and orals) across seven regions.